Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2017-01-18 Director's Dealing
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2017-01-18 English
4
Director's Dealing
2017-01-18 English
4
Director's Dealing
2017-01-18 English
4
Director's Dealing
2017-01-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 9, 2017, by Adaptimmune Therapeutics plc. It announces the release of updated corporate presentation materials attached as Exhibit 99.1. The text explicitly states that the presentation materials are attached and incorporated by reference, and the document itself is short (3497 characters). There are no financial statements or detailed financial data included in this filing. According to the 'Menu vs Meal' rule, this is an announcement of a report (presentation materials), not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-01-09 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 9, 2017, for Adaptimmune Therapeutics plc. It reports "Other Events" including FDA acceptance of an IND application, a milestone in a collaboration agreement with GSK, and an executive appointment. The document includes press releases as exhibits but does not contain financial statements or detailed financial data. The content is typical of a current report disclosing material events outside of periodic financial reports. Therefore, it is classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-01-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.